Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|7|592-597

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.7, 2015-07, pp. : 592-597

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 577-583

John Wiley & Sons Inc

Access to resources Recommend Favorite

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 584-591

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Desensitization to Imiglucerase of an Adult Patient Diagnosed with Type I Gaucher Disease

By  

International Archives of Allergy and Immunology, Vol. 160, Iss. 2, 2012-09 ,pp. : 215-217

Karger

Access to resources Recommend Favorite

Impact of severe haemophilia A on patients' health status: results from the guardian™ 1 clinical trial of turoctocog alfa (NovoEight®)

By  

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : 451-457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vertebral fractures in Gaucher disease type I: data from the French “Observatoire” on Gaucher disease (FROG)

By Javier R.-M.   Hachulla E.   Rose C.   Gressin V.   Chérin P.   Noël E.   Roux-Serratrice C.   Dobbelaere D.   Hartmann A.   Jaussaud R.   Clerson P.   Grosbois B.   Roux C.  

Osteoporosis International, Vol. 22, Iss. 4, 2011-04 ,pp. : 1255-1261

Springer Publishing Company

Access to resources Recommend Favorite